Phase i dose-escalation study of vb-111, an antiangiogenic virotherapy, in patients with advanced solid tumors
Brenner, A. J. Cohen, Y. C. Breitbart, E. Bangio, L. Sarantopoulos, J. Giles, F. J. Borden, E. C. Harats, D. Triozzi, P. L.
Brenner, A. J.
Cohen, Y. C.
Breitbart, E.
Bangio, L.
Sarantopoulos, J.
Giles, F. J.
Borden, E. C.
Harats, D.
Triozzi, P. L.
Identifiers
http://hdl.handle.net/10379/10531
https://doi.org/10.13025/28467
https://doi.org/10.13025/28467
Repository DOI
Publication Date
2013-04-15
Keywords
Type
Article
Downloads
Citation
Brenner, A. J. Cohen, Y. C.; Breitbart, E.; Bangio, L.; Sarantopoulos, J.; Giles, F. J.; Borden, E. C.; Harats, D.; Triozzi, P. L. (2013). Phase i dose-escalation study of vb-111, an antiangiogenic virotherapy, in patients with advanced solid tumors. Clinical Cancer Research 19 (14), 3996-4007
Abstract
Funder
Publisher
American Association for Cancer Research (AACR)
Publisher DOI
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland